The creator of Valeant, Michael Pearson, figured out that with the right class of investors who embraced his methods to create higher, tax-aided earnings per share, he could pretty much roll everyone in the game, Cramer said.
"It is an unpalatable situation. It is all that the drug execs can focus on. And it won't play out until Valeant is so small it doesn't matter and the election dynamic resolves itself," Cramer said.
Read more from Mad Money with Jim Cramer
Cramer Remix: Troubled sector worth speculation
Cramer: Bye-bye Q1, biggest lessons learned
Cramer: Biotech is a land mine about to go off
So, with a new quarter now beginning on Wall Street and Bernie Sanders still running longer than Cramer thought, Valeant still has the ability to cause mayhem for the stock market. The damage seems completely unchecked to Cramer, with only the occasional up day for Valeant providing any relief.
The problem is that Valeant won't go down without swinging, and as long as it remains on its feet, the drug group simply cannot advance for any sustained period of time.
Cramer considers this situation to be an unholy alliance, where there is no referee or group out there to police it to kick it out of the industry.
"Until Valeant settles, I think this bear market in pharma can't end and the money will simply continue flowing into other sectors," Cramer said.
Valeant did not immediately return CNBC calls for comment.